BridgeBio Pharma, Inc. (BBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 250M 500M 750M Q3 '21: 57M Q4 '21: 69.7M Q1 '22: 70.9M Q2 '22: 90.7M Q3 '22: 88.7M Q4 '22: 77.6M Q1 '23: 77.8M Q2 '23: 5.7M Q3 '23: 9.4M Q4 '23: 9.3M Q1 '24: 218.6M Q2 '24: 219.1M Q3 '24: 217.8M Q4 '24: 221.9M Q1 '25: 127.4M Q2 '25: 235.8M Q3 '25: 353.8M Q4 '25: 502.1M Q1 '26: 580M Q2 '26: 713.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 250M 500M 750M Q4 '22: 74.2M Q1 '23: 75M Q2 '23: 3M Q3 '23: 6.9M Q4 '23: 6.9M Q1 '24: 216.2M Q2 '24: 216.7M Q3 '24: 215.4M Q4 '24: 218M Q1 '25: 121.5M Q2 '25: 226.8M Q3 '25: 338.8M Q4 '25: 481.1M Q1 '26: 551.7M Q2 '26: 673.4M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: -538.5M Q4 '21: -576.6M Q1 '22: -582.8M Q2 '22: -569M Q3 '22: -548.6M Q4 '22: -512.2M Q1 '23: -464.7M Q2 '23: -530.6M Q3 '23: -559.2M Q4 '23: -607.4M Q1 '24: -480.9M Q2 '24: -510.3M Q3 '24: -544.4M Q4 '24: -593M Q1 '25: -697.7M Q2 '25: -656.4M Q3 '25: -609.9M Q4 '25: -523.4M Q1 '26: -525M Q2 '26: -497.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-900M -600M -300M 0 300M 600M 900M Q3 '21: -569.2M Q4 '21: -586.5M Q1 '22: -616.7M Q2 '22: -517.2M Q3 '22: -496.4M Q4 '22: -484.7M Q1 '23: -426.1M Q2 '23: -584.2M Q3 '23: -623.5M Q4 '23: -653.3M Q1 '24: -546.7M Q2 '24: -461.5M Q3 '24: -446.3M Q4 '24: -543.3M Q1 '25: -676.8M Q2 '25: -785M Q3 '25: -805.7M Q4 '25: -732.9M Q1 '26: -729.9M Q2 '26: -702M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 15M 30M 45M Q4 '21: 3.1M Q1 '22: 4.1M Q2 '22: 4.7M Q3 '22: 4M Q4 '22: 3.4M Q1 '23: 2.7M Q2 '23: 2.6M Q3 '23: 2.5M Q4 '23: 2.4M Q1 '24: 2.4M Q2 '24: 2.4M Q3 '24: 2.4M Q4 '24: 3.9M Q1 '25: 5.9M Q2 '25: 9M Q3 '25: 14.9M Q4 '25: 21M Q1 '26: 28.3M Q2 '26: 39.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: -460.3M Q4 '21: -497.9M Q1 '22: -507.8M Q2 '22: -446.5M Q3 '22: -460.1M Q4 '22: -419.5M Q1 '23: -403.2M Q2 '23: -486.1M Q3 '23: -496.1M Q4 '23: -527.7M Q1 '24: -602.9M Q2 '24: -414.9M Q3 '24: -450.2M Q4 '24: -520.7M Q1 '25: -500.4M Q2 '25: -655.8M Q3 '25: -584.8M Q4 '25: -445.9M Q1 '26: -444M Q2 '26: -434.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: -473.2M Q4 '21: -511.2M Q1 '22: -519.9M Q2 '22: -458.8M Q3 '22: -466.7M Q4 '22: -424.3M Q1 '23: -407.2M Q2 '23: -488.1M Q3 '23: -497.8M Q4 '23: -529M Q1 '24: -604.9M Q2 '24: -416.5M Q3 '24: -451.5M Q4 '24: -521.7M Q1 '25: -500.7M Q2 '25: -656.6M Q3 '25: -585.9M Q4 '25: -447M Q1 '26: -445.1M Q2 '26: -435.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '21: 146.8M Q3 '21: 146.7M Q1 '22: 145.9M Q2 '22: 146.7M Q3 '22: 147.9M Q1 '23: 152.6M Q2 '23: 160.5M Q3 '23: 163.3M Q1 '24: 178.7M Q2 '24: 187.6M Q3 '24: 188.5M Q1 '25: 190.1M Q2 '25: 190.5M Q3 '25: 191.9M Q1 '26: 194.8M Q2 '26: 195.8M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '20: -3.41 Q4 '20: -3.80 Q1 '21: -4.20 Q2 '21: -3.83 Q3 '21: -3.91 Q4 '21: -3.92 Q1 '22: -4.09 Q2 '23: -3.75 Q3 '23: -3.90 Q4 '23: -3.94 Q1 '24: -3.22 Q2 '24: -2.63 Q3 '24: -2.41 Q4 '24: -2.87 Q1 '25: -3.55 Q2 '25: -4.11 Q3 '25: -4.20 Q4 '25: -3.77 Q1 '26: -3.73 Q2 '26: -3.56 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.